TETRATHERIX LIMITED
ASX:TTXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 99.3% of what they think they own, once every option and right converts.
2 cash raises in 24 months; share count grew 5% in 24 months
TETRATHERIX LIMITED's ordinary share count grew 10.8% between September 2025 and August 2026, to 53M shares. The company raised capital twice in that period, for total disclosed proceeds of A$40.6M, most recently a A$15.6M Placement and SPP in May 2026. Options and rights on issue could convert into 390,996 new shares, equal to 0.7% of the current share count, of which 0% are in the money at the current share price; an expiry date for these securities is not on record. At the June 2026 quarter the company reported A$34.6M in available cash, and its latest reported net cash flow was non-negative, so no funding-runway figure applies. No proposed securities issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 24 Aug 2026 | 2A · quoted issue | TTX : ORDINARY FULLY PAID | 29.5M | Appendix 2A |
| 1 July 2026 | 3G · unquoted | TTX : ORDINARY FULLY PAID | 29.5M | Appendix 3G |
| 22 June 2026 | 2A · quoted issue | TTX : ORDINARY FULLY PAID | 29.5M | Appendix 2A |
| 18 June 2026 | 2A · quoted issue | TTX : ORDINARY FULLY PAID | 29.4M | Appendix 2A |
| 2 June 2026 | 2A · quoted issue | TTX : ORDINARY FULLY PAID | 29.3M | Appendix 2A |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (29.5M) need not equal the current count above (53.1M).
Capital raises
2 cash raises in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 391k of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| TTXAG | Performance rights | Condition-triggered | — | — | 391k | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.